Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Vabicaserin in Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, men and women, aged 18 to 65.~* Hospitalization because of an acute exacerbation of schizophrenia with a diagnosis of schizophrenia established greater than 1 year.~* Ability to remain hospitalized for the duration of the screening period and for 4 weeks of double-blind treatment.~Exclusion Criteria:~* Current Axis I primary psychiatric diagnosis other than schizophrenia (DSM-IV-TR criteria).~* Current diagnosis or history of substance abuse or dependence (DSM-IV-TR criteria), including alcohol (except for nicotine), within 3 months before baseline (day -1).~* Subjects taking high or chronic doses of benzodiazepine at the screening evaluation who, in the investigator's judgment, would be likely to have severe withdrawal symptoms upon discontinuation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): 4mg/day
- 3 (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).